Bloodstream Infection of Carbapenem-Resistant Proteus Mirabilis
NCT ID: NCT06542965
Last Updated: 2024-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
67 participants
OBSERVATIONAL
2018-01-01
2023-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chronic Suppurative Otitis Media Microbiology
NCT06424704
Comparison of Bacterial Contamination Rates Between Isolation and Non-isolation Rooms
NCT01671358
Study of Methicillin-resistant Staphylococcus Aureus (MRSA) Isolated From Infected Patients in Brazil
NCT01359358
Clinical Evaluation of the Residual Antimicrobial Activity
NCT04495920
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics
NCT03162250
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Demographic characteristics of the patients, concomitant chronic diseases, Charlson comorbidity index (CCI), hospital and intensive care unit (ICU) hospitalization and number of days in the last year, history and type of invasive intervention in the last three months (surgical-invasive), history of antibiotic use in the last three months and types of antibiotics used (Penicillin, cephalosporin, quinolone, carbapenem, tigecycline, colistin, aminoglycoside), hospitalization unit, total length of hospitalization, sample collection unit, growth result and antibiogram, clinical and laboratory data of the day of growth, sepsis and septic shock evaluated according to systemic inflammatory response syndrome (SIRS) criteria, 30-day mortality and patient outcome information were recorded.
Carbapenemase-producing gene regions were investigated by Polymerase Chain Reaction (PCR) in accessible samples of patients with carbapenem-resistant P. mirabilis growth in blood cultures.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case (Patients with carbapenem-resistant P. mirabilis)
Patients with carbapenem-resistant P. mirabilis (CRPM) growth in blood culture were included in the case group
Non-Interventional Research
Non-Interventional Research
Control (Patients with carbapenem- susceptible P. mirabilis)
Patients with carbapenem- susceptible P. mirabilis (CSPM) growth in blood culture were included in the control group
Non-Interventional Research
Non-Interventional Research
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Non-Interventional Research
Non-Interventional Research
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* P. mirabilis growth in blood cultures
Exclusion Criteria
* Recurrent growths of the same patient
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dokuz Eylul University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cağlar Iirmak
Principal Investigator, Medical Specialists in Infectious Diseases
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Çağlar IRMAK
Role: PRINCIPAL_INVESTIGATOR
Dokuz Eylul University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dokuz Eylül University
Izmir, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DEU-INF-IRMAK-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.